Table Graph
      published meta-analysis   sensitivity analysis   studies

Vitamin D in COVID-19 mild to moderate - Summary of results

OutcomeTE95% CInkI2ROBPub. bias 14-days deathsdetailed resultsCOVIT-TRIAL, 2022 (REV) 1.84 [0.74; 4.56] 1.84[0.74; 4.56]COVIT-TRIAL, 2022 (REV)10%254NAnot evaluable death D28detailed resultsCOVIT-TRIAL, 2022 (REV) 1.13 [0.57; 2.22] 1.13[0.57; 2.22]COVIT-TRIAL, 2022 (REV)10%252NAnot evaluable deathsdetailed resultsCOVIT-TRIAL, 2022 (REV) 1.13 [0.57; 2.22] 1.13[0.57; 2.22]COVIT-TRIAL, 2022 (REV)10%252NAnot evaluable0.55.01.0relative treatment effectwww.metaEvidence.org2024-05-06 05:07 +02:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 90 - treatments: 734,1439 - roots T: 290

- About us - Contact us - Method - RSS Made with in Lyon - Credits - Privacy policy - Licence Creative Commons